Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

Market Cap	36.68B -27.6%
Revenue (ttm)	4.52B +13.4%
Net Income	676.45M +12.4%
EPS	0.60 +11.2%
Shares Out	1.11B
PE Ratio	54.80
Forward PE	n/a
Dividend	0.55 (1.82%)
Ex-Dividend Date	May 26, 2026

Volume	41,166,364
Open	29.96
Previous Close	30.15
Day's Range	29.44 - 33.17
52-Week Range	29.25 - 70.99
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About SHE:002294

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale of high-end interventional medical devices, such as cardiovascular and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 4,087
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002294

Financial Performance

In 2025, SHE:002294's revenue was 4.35 billion, an increase of 8.48% compared to the previous year's 4.01 billion. Earnings were 651.50 million, an increase of 8.30%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 29, 2026

Data Sources Report a data error